Eli Lilly's eloralintide shows promising early results for weight loss and health benefits

Eli Lilly's new weight loss drug shows promising early trial results, potentially leading to greater weight loss and health benefits. The drug, eloralintide, an amylin analog, helped participants lose between 9.5% and 20.1% of their body weight, with improvements in blood pressure and inflammation markers. Eli Lilly plans to begin phase 3 trials, aiming to enroll patients by year-end, as other companies also explore amylin analogs for obesity treatment.